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Abstract
Background: Early recognition and prompt and appropriate antibiotic treatment can significantly reduce mortality from
serious bacterial infections (SBI). The aim of this study was to evaluate the utility of five markers of infection: C-reactive
protein (CRP), procalcitonin (PCT), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), CD163 and high
mobility group box-1 (HMGB1), as markers of SBI in severely ill Malawian children.
Methodology and Principal Findings: Children presenting with a signs of meningitis (n=282) or pneumonia (n=95), were
prospectively recruited. Plasma samples were taken on admission for CRP, PCT, sTREM-1 CD163 and HMGB1 and the
performance characteristics of each test to diagnose SBI and to predict mortality were determined. Of 377 children, 279
(74%) had SBI and 83 (22%) died. Plasma CRP, PCT, CD163 and HMGB1 and were higher in HIV-infected children than in HIV-
uninfected children (p,0.01). In HIV-infected children, CRP and PCT were higher in children with SBI compared to those
with no detectable bacterial infection (p,0.0005), and PCT and CD163 were higher in non-survivors (p=0.001, p=0.05
respectively). In HIV-uninfected children, CRP and PCT were also higher in children with SBI compared to those with no
detectable bacterial infection (p,0.0005), and CD163 was higher in non-survivors (p=0.05). The best predictors of SBI were
CRP and PCT, and areas under the curve (AUCs) were 0.81 (95% CI 0.73–0.89) and 0.86 (95% CI 0.79–0.92) respectively. The
best marker for predicting death was PCT, AUC 0.61 (95% CI 0.50–0.71).
Conclusions: Admission PCT and CRP are useful markers of invasive bacterial infection in severely ill African children. The
study of these markers using rapid tests in a less selected cohort would be important in this setting.
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Introduction
Serious bacterial infection (SBI) is a major cause of morbidity
and mortality in children in the developing world and is
responsible for about 60% of childhood mortality. Community-
acquired bacteraemia has been demonstrated to be a major cause
of death in children admitted to a rural hospital in Kenya,
accounting for a quarter of all in-hospital deaths [1]. Early
recognition and appropriate antibiotic treatment can significantly
reduce morbidity and mortality [2,3].
Various diagnostic markers of sepsis have been suggested to
facilitate early diagnosis of serious bacterial infection (SBI) and
to inform prognosis, in a variety of clinical settings in different
patient groups. These markers include C-reactive protein
(CRP), procalcitonin (PCT), soluble triggering receptor ex-
pressed on myeloid cells-1 (sTREM-1), haemoglobin scavenger
receptor (CD163) and High Mobility Group Box 1 (HMGB1),
but results have been inconsistent and variable depending on
the selection criteria of patients [4,5,6,7]. Procalcitonin (PCT)
levels begin to increase 3–4 hours after injection of an endotoxin
stimulus in human subjects, peak at about 6 hours and then
plateau for up to 24 hours [8]. In contrast, C-reactive protein
(CRP) levels rise between 12 and 18 hours after bacterial
challenge [8].
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6621TREM-1 is a cell-surface receptor and its expression is up-
regulated on phagocytic cells in the presence of bacteria and fungi.
TREM-1 is shed from the membrane of activated phagocytes and
is present in a soluble form, sTREM-1, in body fluids. TREM-1
expression on monocytes is significantly higher in septic shock
patients than non-septic patients [9].
Haemoglobin scavenger receptor (CD163) is exclusively ex-
pressed in the monocyte-macrophage cell lineage. It is involved in
endocytosis of haptoglobin-haemoglobin complexes. Soluble
haemoglobin scavenger receptor (sCD163) is a product shed from
the monocyte-macrophage membrane. Increased plasma levels of
sCD163 have been observed in patients with severe sepsis [4],
bacterial meningitis [10], and bacteraemia [11]. sCD163 was
found to be a reliable predictor of a fatal outcome in adult patients
with pneumococcal bacteraemia [12].
HMGB1, a nuclear protein, is a delayed mediator of inflamma-
tion, with release occurring about 12–18 hours after classical early
pro-inflammatory mediators such as TNF and IL-1. High levels of
HMGB1 are seen in severe sepsis and septic shock, with levels
remaining high in non-survivors [13,7].
The mortality from community acquired bacteraemia among
children in sub-Saharan Africa is significant, with a third of deaths
occurring on the day of admission and two thirds within two days
[1]. What is needed is a rapid and reliable bedside test that
accurately predicts SBI, and opens up an opportunity to either
initiate antibiotics early or to identify children at highest risk of
death in whom second line antibiotics or aggressive fluid therapy
might be targeted. PCT and CRP have been evaluated in the
developing world setting [14,15,16] but the assessment of
sTREM-1, CD163 and HMGB1 as markers of SBI has never
previously been performed in African children. The aim of this
study was to evaluate the diagnostic and prognostic utility of these
markers in diagnosing SBI in Malawian children presenting to the
accident and emergency department with signs and symptoms
suggestive of meningitis or pneumonia.
Methods
We prospectively enrolled children between April 2004 and
October 2006 who presented to the Accident and Emergency
Department and the Admissions Unit of Queen Elizabeth
Central Hospital, Blantyre, Southern Malawi, which serves a
population of approximately one million. This is a government-
funded teaching and referral hospital with 150 paediatric beds,
although paediatric inpatients are often in excess of 300. Children
aged 2 months to 16 years identified as possible cases of
pneumonia (respiratory rate$50/min for children ,12 months
and $40/min for children $12 months) or meningitis (stiff neck,
bulging fontanelle, fever and convulsions) were consecutively
recruited into the study. Children with significant co-existing co-
morbidities (eg congenital heart disease, chronic lung disease,
end-stage AIDS) were excluded. Haemophilus influenzae b vaccina-
tion is administered routinely in the childhood immunisation
schedule in Malawi.
The primary outcome measure was bacteriological confirmation
of infection (SBI) and the secondary outcome measure was death/
survival in hospital, Afebrile children, without malaria parasitae-
mia, from the same villages as the cases, were used as controls. All
controls were HIV-uninfected.
Ethical approval for this study was granted from The College of
Medicine Research Committee (COMREC), Malawi and The
Liverpool School of Tropical Medicine Research Ethics Commit-
tee. Parents or guardians gave written informed consent for
children to enter the study.
Definitions
Cases (n=377). Children who presented with signs and sym-
ptoms of meningitis or pneumonia.
Bacterial pneumonia (n=95). Clinical signs of pneumonia
(cough, fever, crackles, bronchial breath sounds) and radiological
evidence of pneumonia (focal or lobar consolidation).
Bacterial meningitis (n= 282). Clinical signs of meningitis,
and abnormal CSF cell count, .10 cells/ml.
Serious bacterial infection (SBI+ve) (n=280). Children
who presented with either bacterial meningitis or bacterial
pneumonia, in whom a bacterial pathogen was identified by culture,
polysaccharide antigen test or PCR (Streptococcus pneumoniae, Neisseria
meningitidis, and Haemophilus influenzae b).
No detectable bacterial infection (SBI-ve) (n=97). Chil-
dren who presented with bacterial meningitis or bacterial
pneumonia, but who were negative for any bacteria on culture,
polysaccharide antigen test or PCR (S.pneumoniae, N.meningitidis, and
H. Influenzae b).
Invasive pneumococcal disease (IPD) (n=230). Children
with SBI in whom S. pneumoniae was identified (by culture,
microscopy, antigen testing or PCR) from one or more of the
following normally sterile body sites: blood, cerebrospinal fluid,
lung aspirate.
Microbiological methods
For blood culture, 1–2 mls of venous blood was drawn after
swabbing the venepuncture site with alcohol. When this sample
was taken at the same time as the other study blood samples,
t h eb l o o dc u l t u r eb o t t l ew a si n o c u l a t e df i r s t .T h eB a c T / l e r t3 D
automated system was used (BioMerieux), and isolates
were identified using standard techniques[17]. Diphtheroids,
micrococci, Bacillus species, Coagulase-negative staphylococci
and mixed growth of skin flora were considered to be
contaminants.
CSF samples were examined microscopically for total white cell
count and differential. Gram stain was performed on all samples
that were turbid or had .8 white cells/mL. After centrifugation,
deposits were cultured on sheep blood agar and incubated in a
candle jar at 37 uC for 48 h. 5 ml brain-heart infusion broth with
1% Vitox (Oxoid, Basingstoke, UK) was added to the remaining
deposit for enrichment culture. This broth was incubated for 48 h
and the centrifuged deposit was cultured onto sheep blood agar,
which was also incubated for 48 h. Latex agglutination tests using
the Wellcogen bacterial antigen kit (Abbott Murex Biotech,
Dartford, UK) were performed on CSF samples suggestive of
meningitis, but with negative Gram staining.
All blood and CSF samples were assayed using a multiplex PCR
assay for the detection of N. meningitidis, H. influenzae and S.
pneumoniae as previously described [18]. The PCR assay for the
quantification of pneumococcal DNA has been described
previously [19].
Malaria diagnosis
Microscopic diagnosis was based on best standard practice of
district-hospital and health-centre general laboratories in sub-
Saharan Africa. In brief, blood films were stained with Fields stain
and parasite densities estimated from thick films by counting the
number of parasites per 200 white blood cells (WBC) assuming a
total count of 8000/ml.
CRP and PCT assay
The assays for CRP and PCT measurement have previously
been described [20].
Markers of Bacterial Infection
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TREM-1, CD163 and HMGB1 were measured using a
commercially available sandwich enzyme immunoassays accord-
ing to the manufacturer’s instructions (TREM-1: Quantikine,
R&D Systems, Minneapolis, USA, CD163: Bachem (UK), St
Helens, Merseyside, UK, and HMGB1: Shino-test, Kanagawa,
Japan).
Cytokine determination
Cytokine determination was performed in plasma using a
commercial 27-plex Bioplex Cytokine kit (Bio-Rad Laboratories
Inc, California, USA) that utilises Luminex 100 technology in the
Bio-plex Protein Array System according to the manufacturer’s
instructions (Bio-Rad Laboratories Inc, California, USA).
Statistical analysis
Statistical analysis was performed using SPSS for Windows,
version 15.0, (Illinois, USA). The data when plotted did not follow
a normal distribution, and therefore the Mann Whitney Test was
used to compare distributions, and Spearman’s correlation
coefficient for correlations of clinical and laboratory variables.
The General Linear Model was used to explore the effects of
confounding factors (HIV status, neutrophil count, age, sex,
duration of symptoms and previous antibiotic administration) on
comparison groups. Cut-off values to determine ‘‘normal’’ and
‘‘abnormal’’ values (Figure 1) were derived from previous
published studies and the following were used; CRP#10 mg/l,
PCT#0.5 ng/ml, TREM-1#25 ng/ml, CD163#5000 ng/ml
and HMGB1#5 ng/ml [7,10,21]. Receiver operator characteris-
tic (ROC) curves were used to determine the areas under the curve
(AUCs) with 95% confidence intervals for the five markers to
predict SBI and death. The laboratory assays for bacteriological
confirmation and the markers of infection were performed by
investigators blinded to the clinical data. The clinicians involved in
managing the cases were not involved in performing any of the
laboratory assays.
The study was reported according to STARD guidelines which
includes method of recruitment of patients, orders of test
execution, and numbers of patients undergoing the tests under
evaluation and the numbers of patients with the reference
standard [22,23] (Figure 1).
Results
Patient characteristics
There were 377 children who presented with signs of pneumonia
(n=95) or meningitis (n=282). In the cases, there were 215 males
(57%) and median age was 2.3 years, interquartile range (IQR) (0.8
to 6.1 years). In the controls there were 13 males (87%) and median
age was 10.0 years (IQR 6 to 13 years). Of the cases, 190 (50.4%)
were HIV-infected, and none of the controls were HIV-infected.
Overall, 83 children (22%) died. In 13/360 children, the blood film
was positive for malaria parasites. In these 13 children, CRP, s-
Figure 1. Flow diagram showing the number of patients undergoing index tests and the number of patients with SBI and
meningitis and pneumonia, according to STARD guidelines.
doi:10.1371/journal.pone.0006621.g001
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for malaria parasites, but these differences were not significant. Of
the children with malaria parasitaemia, 2 children had 4+
parasitaemia, 1 had 3+, 2 had 2+, and 8 had 1+. In 5 of the
children with parasitaemia, blood cultures were also positive; S.
pneumoniae: 3 children had 1+ and 1child had 2+ parasitaemia, and
Salmonella Enteritidis: 1 child had 1+ parasitaemia.
A total of 280 children (74%) had serious bacterial infection
(SBI+ve), of which 131 (47%) were blood culture positive, 144 (52%)
were HIV-infected, and 67 (24%) died. Table 1 compares the
baseline patient characteristics in the SBI+ve and SBI-ve groups.
The predominant pathogen causing disease was S. pneumoniae
(n=230, 61%), followed by N. meningitidis (n=17, 4.5%), H.influenzae
(Hib n=16, non- Hib n=4, total 4.2%) and Salmonella enterica (S.
enterica serovar Typhimurium n=9, S. enterica serovar Enteritidis
n=2, total: 2.9%). In 97 children (26%) no pathogen was identified
(Figure 2). In the SBI-ve group, 46 (47%) were HIV-infected and 16
(16%) died. Blood culture positivity was reduced in those who
reported previous antibiotic use (33% versus 67%, p=0.004).
CRP, PCT, s-TREM-1, CD163 and HMGB1 in HIV-infected
and HIV-uninfected children
Median CRP, PCT, s-TREM-1, CD163 and HMGB1 values
were higher in HIV-infected compared to HIV-uninfected cases
(277.3 versus 239.0 mg/l, 34.4 versus 16.5 ng/ml, 52.8 versus
61.6 ng/ml, 6880.7 versus 5329.8 ng/ml and 7.0 versus 5.8 ng/ml,
p=0.007, p,0.0005, p=0.08, p=0.001, p=0.004, respectively).
Subgroup comparisons of CRP, PCT, s-TREM-1, CD163
and HMGB1 in HIV-infected children
Median PCT values were significantly higher in bacterial
meningitis compared to bacterial pneumonia, and median s-
TREM-1 was significantly lower (Table 2). Median CRP, PCT,
and HMGB1 values were significantly higher in SBI+ve compared
to SBI-ve cases. Within SBI+ve cases, s-TREM-1 was significantly
higher in infections other than IPD compared to IPD. Median
PCT and CD163 values were significantly higher in non-survivors
compared to survivors (Table 2).
Sub group comparisons of CRP, PCT, s-TREM-1, CD163
and HMGB1 in HIV-uninfected children
There was no significant difference in median CRP, PCT, s-
TREM-1, CD163 and HMGB1 values between bacterial
meningitis compared to bacterial pneumonia. Median CRP and
PCT values were significantly higher in SBI+ve compared to SBI-
ve cases. Within SBI+ve cases, s-TREM-1 was significantly higher
in infections other than IPD compared to IPD, and CRP was
significantly higher in IPD compare to infections other than IPD.
Median CD163 values were significantly higher in non-survivors
compared to survivors (Table 2).
Correlations between CRP, PCT, s-TREM-1, CD163 and
HMGB1 and pro- and anti- inflammatory cytokines
There were weak but significant correlations between the five
markers of infection and the pro- and anti-inflammatory cytokines,
Table 1. Characteristics of children with serious bacterial infection (SBI) and those with no bacterial infection (NBI) detected.
Numeric value are median and interquartile range (IQR).
SBI (n=280) NBI (n=97) p value
Age (years) 2.0 2.5 0.77
median(IQR) (0.6–6.9) (1.0–5.7)
Males 154 (55%) 61 (63%) 0.18
Duration of symptoms (days) median(IQR) 3 (2–5) 3 (2 – 5) 0.76
Previous antibiotics (%) 123 (44%) 37 (38%) 0.32
Meningitis 235 (84%) 47 (49%) ,0.0005
Mortality (%) 68 (24%) 15 (15%) 0.07
HIV-infected (%) 145 (52%) 45 (47%) 0.41
Height for age Z score ,23 (severe stunting) (%) 42/272 (15%) 16/91 (18%) 0.63
Weight for height Z score ,23 (severe wasting) (%) 37/218 (17%) 11/82 (13%) 0.45
White cell count (WCC)610
9/l 12.6 13.8 0.09
median(IQR) (7.8–20.0) (10.0–20.4)
Neutrophil count610
9/l 10.6 8.9 0.78
median(IQR) (4.6–16.3) (5.5–15.5)
doi:10.1371/journal.pone.0006621.t001
Figure 2. Pie chart showing aetiology of serious bacterial
infection.
doi:10.1371/journal.pone.0006621.g002
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and interleukin-10 (IL-10). These are shown in Table 3.
Discriminatory power of CRP, PCT, s-TREM-1, CD163 and
HMGB1 in predicting SBI or death using Receiver
Operator Characteristic (ROC) curves
TheareasundertheROCcurve(AUCs)forCRP,PCT,sTREM-
1, CD163 and HMGB1 in predicting SBI were 0.81 (95% CI
0.73–0.89), 0.86 (95% CI 0.79–0.92) and 0.52 (95% CI 0.43–0.61),
0.50 (95% CI 0.41–0.60) and 0.59 (95% CI 0.50–0.69) respectively.
The AUCs for CRP, PCT, sTREM-1, CD163 and HMGB1 in
predicting death were 0.43 (95% CI 0.33–0.53), 0.61 (95% CI
0.50–0.71) and 0.54 (95% CI 0.44–0.64), 0.56 (95% CI 0.46–0.67)
and 0.56 (95% CI 0.46–0.65) respectively (Figures 3 and 4).
Discussion
We have shown that PCT is the best diagnostic marker of SBI in
Malawian children presenting with signs of severe sepsis. Although
none of the markers demonstrated any value in predicting death,
PCT was also the best prognostic marker in children with severe
sepsis. PCT and CRP were significantly increased in SBI, and these
differences remain significant when stratified by HIV status. CD163
is significantly increased in non-survivors, and PCT is significantly
increased in HIV-infected survivors. Although the performance of
CRP was similar to that of PCT in predicting SBI, the rapid kinetics
of PCT compared to CRP make it more likely to detect sepsis early,
and could be used to initiate antibiotics early in children at risk of
sepsis. Our data are consistent with those of Palmer in which CRP
did not show enough sensitivity and specificity to be used alone as a
predictorof SBIininfants [14], and the study by Madhi whereCRP
andPCTimprovedthediagnosisofradiologicalpneumonia[16].In
contrast, a study by Cheung found that CRP was a better
discriminator of pneumonia than PCT [15]. Our findings also
support those of Moller [12], which showed that CD163 was
superior to other markers in predicting fatal outcome in adults with
pneumococcal bacteraemia.
It is inconceivable that clinicians would ever withhold
parenteral antibiotics from children with signs of pneumonia or
meningitis in a setting where a quarter of children die, and where
diagnostic facilities are not optimal. However, our study suggests
that in children who would not necessarily receive parenteral
antibiotics (i.e. sick enough to be admitted to hospital but not
meeting WHO syndromic criteria for parenteral antibiotics), the
availability of a rapid PCT test could be clinically very useful.
Strategies to reduce the global burden of sepsis include
prevention through immunization, early recognition and treatment
and development of new diagnostics and therapeutics[3]. Our study
suggests that a rapid test for PCT could help to identify children
with SBI but without signs of severe sepsis, and children in whom
aggressive intravenous fluid resuscitation and adjunctive therapies
such as low-dose hydrocortisone, might be targeted. Our study also
suggests that PCT could potentially be used to define disease
severity objectively for the purpose of comparing groups in
pathogenesis studies, and to define patients who might be eligible
for randomised controlled trials of new therapies in bacterial sepsis.
A semi-quantitative immunochromatographic bedside test for
PCT is currently available (Brahms Diagnostica GMBH, Berlin)






















Meningitis 279 44 50 7144 6.8 232 18 61 5430 5.8
Pneumonia 276 13 64 5449 7.6 275 8 64 5219 5.5
p=NS p=0.003 p=0.01 p=0.06 p=NS p=NS p=NS p=NS p=NS p=NS
SBI+v e 2 9 1 4 65 36 9 0 0 7 . 6 2 5 3 2 26 55 3 2 4 5 . 9
SBI–ve 135 3 54 5544 6.0 127 4 57 5601 4.9
p,0.0005 p,0.0005 p=NS p=NS p=0.05 p,0.0005 p,0.0005 p=NS p=NS p=NS
IPD 294 48 52 6948 7.6 277 25 57 5324 5.8
SBI(other than IPD) 279 41 70 6160 6.9 247 55 114 5549 6.5
p=NS p=NS p=0.02 p=NS p=NS p,0.0005 p=NS p=0.01 p=NS p=NS
Survivor 280 24 54 5783 6.9 247 14 61 5243 5.6
Non-survivor 256 90 52 7972 7.7 201 19 68 6308 6.5
p=NS p=0.001 p=NS p=0.05 p=NS p=NS p=NS p=NS p=0.05 P=NS
(NS=non-significant).
doi:10.1371/journal.pone.0006621.t002
Table 3. Correlation between markers of infection and pro-
and anti- inflammatory cytokines (Spearman’s correlation
coefficient. NS=non-significant).
Log IL-6 Log IL-8 Log IL-1Ra Log IL-10
CRP 0.38 0.14 0.33 NS
p,0.0005 p=0.04 p,0.0005
PCT 0.62 0.51 0.63 0.32
p,0.0005 p,0.0005 p,0.0005 p,0.0005
sTREM-1 NS NS NS NS
CD163 0.23 0.15 0.23 NS
p,0.0005 p=0.02 p,0.0005
HMGB1 0.25 0.26 0.21 0.23
p,0.0005 p,0.0005 p=0.001 p,0.0005
doi:10.1371/journal.pone.0006621.t003
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more sensitive bedside assay which uses whole blood, is in
development (PCT Direct, Brahms Diagnostica GMBH, Berlin),
with a sensitivity of 0.2 ng/ml and a range up to 7 ng/ml. It will
use a dedicated PCT reader and is expected to be launched in
2010. This rapid test, if available, could allow PCT to be used in
resource poor settings, as a point-of-care test, to direct clinical
decision making. The success of rapid diagnostic tests in resource-
poor settings has been illustrated by their use the diagnosis of HIV
and malaria. In the study from rural Kenya, the largest such study
ever to be conducted in sub-Saharan Africa, deaths in children
with bacteraemia were rapid, with 33% occurring on the day of
admission, and 70% within two days [1]. This considerable
mortality, within a short interval despite a high standard of care,
highlights the need for rapid and reliable diagnostic tests such as
PCT in this setting.
The strengths of this study are that we studied a large number of
children in whom the clinical phenotype was well described, and in
whom we investigated for the presence of bacterial infection with
culture, antigen testing and PCR. Our study has some limitations;
we studied a selected group of patients (with symptoms and signs of
meningitis or pneumonia), we measured the markers at one time
point only, and we did not investigate the membrane-bound
components of CD163 or TREM-1. Data from other African
studies suggest that both malaria and tuberculosis may increase
levels of CD163 [25,26], but our study did not demonstrate that
malaria co-infection may significantly influence levels of these
markers in acute bacterial infections. A case-control study design
may potentially over-estimate the predictive value of a test, but we
have attempted to eliminate further bias by comparing the tests
using an independent reference standard (microbiologically con-
firmed disease) according to STARD guidelines.
Before we can recommend PCT for more widespread use, we
recommend that the study is repeated in a less selected cohort of
all children presenting with signs suggestive of bacterial infection,
and that a randomised controlled trial (RCT) of PCT be
conducted to assess the potential for PCT-guided management
to reduce mortality. Recent studies of RCTs of PCT-guided
therapy in ICU patients have suggested that PCT-guided decision
making may reduce antibiotic use and shorten PICU stay [27,28].
In conclusion, we have shown that among the five markers tested,
PCT is the best diagnostic and prognostic marker of SBI in
Malawian children with severe sepsis, including those with HIV
infection. This study provides valuable new information about the
performance of these markers in a developing world setting, and
suggests that the study needs to be repeated in a less selected cohort.
Figure 3. ROC curve of CRP, PCT, s-TREM-1, CD163 and HMGB1 as markers of SBI.
doi:10.1371/journal.pone.0006621.g003
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